Clinical Trial Update: A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of ALKS 4230 (nemvaleukin alfa) in combination with pembrolizumab for head and neck squamous cell carcinoma has completed enrollment and posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• ALKS 4230 (Nemvaleukin alfa) (Nemvaleukin alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mural Oncology, Inc | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2024-10-16